首页> 外文OA文献 >Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

【2h】

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

机译：I期I试验刺猬途径抑制剂Vismodegib（GDC-0449）在难治性，局部晚期或转移性实体肿瘤的患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Patricia M. LoRusso; Charles M. Rudin; Josina C. Reddy; Raoul Tibes; Glen J. Weiss; Mitesh J. Borad; Christine L. Hann; Julie R. Brahmer; Ilsung Chang; Walter C. Darbonne; Richard A. Graham; Kenn L. Zerivitz; Jennifer A. Low; Daniel D. Von Hoff;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. [J] . Lorusso PM, Rudin CM, Reddy JC, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第8期

机译：难治性，局部晚期或转移性实体瘤患者的Hedgehog途径抑制剂Vismodegib（GDC-0449）I期试验。
2. Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. [J] . Graham RA, Lum BL, Cheeti S, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第8期

机译：刺猬通路抑制剂Vismodegib（GDC-0449）在患有局部晚期或转移性实体瘤的患者中的药代动力学：α-1酸性糖蛋白结合的作用。
3. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. [J] . Lorusso PM, Jimeno A, Dy G, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第17期

机译：刺猬途径抑制剂vismodegib（GDC-0449）在局部晚期或转移性实体瘤患者中的药代动力学剂量研究。
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory Locally Advanced or Metastatic Solid Tumors [O] . Patricia M. LoRusso, Charles M. Rudin, Josina C. Reddy, -1

机译：患者Hedgehog通路抑制剂Vismodegib（GDC-0449）的I期临床试验难治局部晚期或转移性实体瘤
7. Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma [O] . Nancy M. Nix PharmD BCPS BCOP, Olivia Burdine PharmD, Makeda Walker PharmD 2014

机译：VISMODEGIB：转移或局部晚期基础细胞癌的一流刺猬障碍抑制剂

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

著录项

引文网络

相似文献

相关主题

期刊订阅